Observational studySurgical endoscopy2017
Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
Observational study in Surgical endoscopy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Ten Year Follow-Up After Explantation of the Duodenal-jejunal Bypass Liner.Obesity surgery · 2025Article
- Satiety Hormone LEAP2 After Low-Calorie Diet With/Without Endobarrier Insertion in Obesity and Type 2 Diabetes Mellitus.Journal of the Endocrine Society · 2024Article
- Mechanism of action and selection of endoscopic bariatric therapies for treatment of obesity.Clinical endoscopy · 2024Review
- Exploring the underlying mechanisms of obesity and diabetes and the potential of Traditional Chinese Medicine: an overview of the literature.Frontiers in endocrinology · 2023Review
- Measures of glucose homeostasis during and after duodenal exclusion using a duodenal-jejunal bypass liner in a normoglycemic, nonobese canine model.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2022Article
- Research Progress of Duodenal-Jejunal Bypass Liner in the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Various Novel and Emerging Technologies in Endoscopic Bariatric and Metabolic Treatments.Clinical endoscopy · 2021Article
- A Preclinical Animal Study of Combined Intragastric Balloon and Duodenal-Jejunal Bypass Liner for Obesity and Metabolic Disease.Clinical and translational gastroenterology · 2020Article
- From the Knife to the Endoscope-a History of Bariatric Surgery.Current obesity reports · 2020Review
- Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome.Obesity surgery · 2020Article
- Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.Surgical endoscopy · 2020Observational
- Medical Devices in Obesity Treatment.Current diabetes reports · 2019Review
- Impact of Duodeno-Jejunal Bypass Liner (EndoBarrierTM) Implantation on Insulin Sensitivity in Patients with Type 2 Diabetes Mellitus (T2DM): A Study Protocol for a Pilot Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus.World journal of diabetes · 2018Article
- Endobarrier as a Pre Bariatric Surgical Intervention in High-Risk Patients: a Feasibility Study.Obesity surgery · 2018Article
- Therapeutic luminal coating of the intestine.Nature materials · 2018Article
- Endoscopic Interventions in the Treatment of Obesity and Diabetes.Digestive diseases and sciences · 2018Review
- The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.Obesity surgery · 2018Article
- The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss.Gastroenterology research and practice · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe duodenal-jejunal bypass liner (DJBL) is an endoscopic treatment for patients with type 2 diabetes mellitus (T2DM) and (morbid) obesity. The aim of the current study was to determine its efficacy and safety profile.
methodsInclusion criteria for treatment with a DJBL were: age 18-70 years, BMI 28-45 kg/m
resultsBetween 2011 and 2014, 185 out of 198 patients successfully underwent a DJBL implantation procedure, with an intended implantation time of 12 months. In these 185 patients, body weight decreased by 12.8 ± 8.0 kg (total body weight loss of 11.9 ± 6.9 %, p < 0.001), HbA1c decreased from 67 to 61 mmol/mol (p < 0.001) despite a reduction in anti-diabetic medication, and blood pressure and serum lipid levels all decreased. In total, 57 (31 %) DJBLs were explanted early after a median duration of 33 weeks. Adverse events occurred in 17 % of patients. C-peptide ≥1.0 nmol/L and body weight ≥107 kg at screening were independent predictive factors for success.
conclusionsTreatment with the DJBL in T2DM patients with (morbid) obesity results in improvement in glucose control, a reduction in anti-diabetic medication, and significant weight loss. The largest changes are observed within the first 3-6 months. Initial C-peptide levels and body weight may help to select patients with the greatest chance of success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.